PCM
ACAD icon

Penn Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Penn Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-248,844
Closed -$4.62M – 145
2024
Q1 		$4.62M Buy
248,844
+1,520
+0.6% +$37.7K 0.41% 79
2023
Q4 		$7.77M Sell
247,324
-41,959
-15% -$1M 0.71% 66
2023
Q3 		$6.05M Buy
289,283
+102,280
+55% +$2.78M 0.62% 73
2023
Q2 		$4.48M Buy
+187,003
New +$4.16M 0.44% 75

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Penn Capital Management's ACAD Position: Q2 2024 in Review

Penn Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2024, closing a stake of 248,844 shares — an estimated $4.62M sold.

Penn Capital Management first reported a position in ACAD in Q2 2023 and held it in 4 quarters. The position peaked at $7.77M in Q4 2023. 264 funds tracked by Wall St. Rank hold ACAD as of Q2 2024.

  • Penn Capital Management reported no remaining Acadia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Penn Capital Management sold 248,844 Acadia Pharmaceuticals shares in Q2 2024, an estimated $4.62M.
  • Penn Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2023 and held it in 4 quarters.
  • Penn Capital Management's Acadia Pharmaceuticals position peaked at $7.77M in Q4 2023.
  • 264 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2024.

Based on Penn Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.